

Screening populations at high risk for tuberculosis might improve clinical outcomes and reduce transmission, but the value and cost-effectiveness of population-based screening depend on the uncertain health impact of early tuberculosis detection. In this Personal View, we propose a framework for estimating the incremental health impact of systematic screening, including effects on tuberculosis morbidity, mortality, sequelae, and transmission. Our framework accounts for the timing of screening, relative to when routine diagnosis might occur and when health effects become inevitable.
Infectious Diseases
|15th Jan, 2026
|The Lancet
Infectious Diseases
|15th Jan, 2026
|The Lancet
Infectious Diseases
|15th Jan, 2026
|The Lancet
Infectious Diseases
|15th Jan, 2026
|The Lancet
Infectious Diseases
|15th Jan, 2026
|The Lancet
Infectious Diseases
|15th Jan, 2026
|The Lancet
Infectious Diseases
|15th Jan, 2026
|The Lancet